Ion Exchange (500214) Q1 26/27 earnings summary

Executive summary

• Q1 FY27 consolidated operating income rose 20.1% year-on-year to INR 7,005 Mn, but EBITDA declined 49% to INR 318 Mn, with net profit at INR 31 Mn and a PAT margin of 0.44%.

• The Board approved unaudited standalone and consolidated results for the quarter ended June 30, 2026, reviewed by independent auditors with no material misstatements.

• The company implemented a new segment reporting structure, splitting engineering into treatment solutions, industrial products, and lifecycle services for greater transparency.

• Legacy projects, especially in treatment solutions, continue to impact profitability, but management remains optimistic about future growth as new capacities and international markets ramp up.

• Order book as of June 30, 2026, stood at INR 97,770 Mn, indicating strong future revenue visibility.

Financial highlights

• Q1 FY27 consolidated operating income: INR 7,005 Mn (up 20.1% YoY); EBITDA: INR 318 Mn (down 49.3% YoY); EBITDA margin: 4.54%.

• Net profit: INR 31 Mn (down 93.6% YoY); PAT margin: 0.44%.

• Standalone revenue from operations: INR 6,356 Mn; standalone net profit: INR 114 Mn.

• Order book at INR 97,770 Mn as of June 30, 2026, excluding a $52.83 million Hyundai contract win post-quarter.

• Bid pipeline at INR 9,777 crores, indicating strong future order prospects.

Outlook and guidance

• Management expects improved profitability as Roha plant utilization increases and geopolitical headwinds ease.

• Growth expected from liquidation of existing backlog, new segments, and expanded manufacturing capacity for membranes and standard plants.

• Focus remains on scaling expanded capacities, growing recurring services, and capitalizing on domestic and international opportunities.

• Double-digit profitability is a medium-term goal, with gradual improvement anticipated as legacy projects wind down.

• Strategic shift towards technology-led water and environment solutions to drive growth.